Please login to the form below

Not currently logged in
Email:
Password:

Novartis' Zykadia nears first-line lung cancer label

Hopes to boost slow second-line sales to compete directly with Pfizer’s Xalkori and Roche’s Alecensa 
Novartis

All being well, Novartis could get FDA approval for its ALK inhibitor Zykadia as a first-line treatment for lung cancer within the next six months.

The FDA has started a priority review of the new indication for Zykadia (ceritinib) based on data showing it can improve progression-free survival (PFS) in previously-untreated patients with ALK-positive advanced non-small cell lung cancer (NSCLC).

Patients taking Xalkori invariably relapse, often within 12 months of starting treatment with the drug, due to the development of resistance in tumour cells.

Zykadia was first approved in 2015 as a second-line option for ALK-positive NSCLC patients whose disease had progressed despite earlier treatment with Pfizer/Merck KGaA's rival ALK inhibitor Xalkori (crizotinib) but if the latest filing is successful Novartis will be able to compete head-to-head for newly-diagnosed patients.

Approval will also give Novartis an opportunity to make headway against other competitors in the second-line setting, such as Roche's fast-growing Alecensa (alectinib), which was also approved in the US in 2015 and just got a green light in Europe for post-Xalkori treatment, as well as Ariad's recently filed brigatinib.

At the moment, Novartis' brand is struggling a little. Zykadia brought in $91m in sales last year, with sales actually shrinking in the fourth quarter due to competition in the US market. For comparison, Alecensa sales were around $180m last year while Pfizer booked $927m from Xalkori.

It may be pertinent that Roche released data from a Japanese study last year, which pointed to a significant PFS improvement for Alecensa over Xalkori in the second-line setting, and Novartis will be hoping that approval for first-line use will help it start a comeback.

The FDA priority review is based on phase III ASCEND-4 study results showing 16.6 month PFS in previously untreated ALK-positive metastatic NSCLC patients on Zykadia, more than double the 8.1 months improvement seen in patients treated with chemotherapy.

The US regulator has also awarded Zykadia breakthrough therapy status based on phase III data in patients with metastases to the brain, which could also help position the drug competitively versus its rivals.

Article by
Phil Taylor

23rd February 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics